PCK1, or cytosolic phosphoenolpyruvate carboxykinase, is best known as the rate-limiting enzyme in gluconeogenesis, the process your liver uses to manufacture glucose when food is not available. But research over the past two decades has revealed that PCK1 does far more than keep blood sugar steady during a fast. It helps fat cells recycle fatty acids, maintains acid-base balance in the kidneys, and can even flip direction depending on the body’s energy state, feeding carbon back into the cell’s central energy hub instead of generating glucose. Its connections to fatty liver disease, diabetes, cancer, and a rare but dangerous genetic deficiency make it one of the more medically relevant metabolic enzymes that most people have never heard of.
Making Glucose When You Need It
When you skip a meal or sleep through the night, your blood sugar drops and glucagon rises. In the liver, this hormonal signal sets off a cascade that turns on PCK1. The enzyme catalyzes a specific chemical step: it converts oxaloacetate into phosphoenolpyruvate, consuming GTP in the process. That reaction is the committed step in gluconeogenesis, the pathway that builds new glucose molecules from non-sugar precursors like lactate, amino acids, and glycerol. Without PCK1 working, the liver cannot complete this job.
The transcription factor Foxo1 is a key middleman in this signaling chain. Glucagon activates protein kinase A, which phosphorylates Foxo1 at a specific site, driving it into the nucleus where it turns on the gene for PCK1 and other gluconeogenic enzymes.1Diabetes. Novel Mechanism of Foxo1 Phosphorylation in Glucagon Signaling in Control of Glucose Homeostasis The RNA-binding protein HuR adds another layer of control: during fasting, high-fat feeding, and in animal models of type 2 diabetes, HuR expression rises in the liver and stabilizes the messenger RNA for a transcription factor called C/EBPβ, which in turn boosts PCK1 levels.2PubMed Central. Hepatic HuR modulates glucose metabolism through the C/EBPβ/PCK1 pathway These overlapping control mechanisms ensure that PCK1 is responsive to a wide range of metabolic stresses, not just simple overnight fasting.
Jobs Beyond the Liver
PCK1 does not just live in hepatocytes. In white adipose tissue, it plays a completely different metabolic role: glyceroneogenesis. This is the process by which fat cells synthesize glycerol-3-phosphate, the backbone molecule needed to re-esterify free fatty acids back into stored triglycerides. Without glyceroneogenesis, fat cells would release too many fatty acids into the bloodstream, flooding the liver and muscle with lipids and promoting insulin resistance. Studies in mice have shown that disrupting PCK1 specifically in adipose tissue causes exactly this problem: animals become profoundly insulin resistant, release more fatty acids and glycerol even during insulin infusion, and secrete roughly twice as much insulin at high glucose concentrations as normal mice do.3PubMed Central. Phosphoenolpyruvate carboxykinase (Pck1) helps regulate the triglyceride/fatty acid cycle and development of insulin resistance in mice
This adipose role is clinically relevant because the thiazolidinedione class of diabetes drugs, such as rosiglitazone, works partly by ramping up PCK1 in fat cells. In both rats and human patients with type 2 diabetes, rosiglitazone raised PCK1 messenger RNA in subcutaneous fat by about 2.5-fold. When fat tissue samples from overweight women were treated with the drug in culture, PCK1 mRNA climbed as high as nine-fold while other genes stayed flat, pointing to a selective and direct effect on PCK1 transcription that was followed by increased enzyme activity and glyceroneogenesis.4PubMed. Acute and selective regulation of glyceroneogenesis and cytosolic phosphoenolpyruvate carboxykinase in adipose tissue by thiazolidinediones in type 2 diabetes
In the kidneys, PCK1 has yet another assignment. Renal tubular cells rely on it for acid-base balance, mitochondrial health, and local glucose and lactate metabolism. Deleting PCK1 from kidney cells in mice produces a condition called hyperchloremic metabolic acidosis, in which blood becomes too acidic partly because ammonium excretion drops. The enzyme is also needed for normal mitochondrial function in those cells, so losing it disrupts energy production and lactate handling at the same time.5PubMed Central. PCK1 is a key regulator of metabolic and mitochondrial functions in renal tubular cells
How the Body Flips PCK1’s Direction
One of the more surprising discoveries about PCK1 is that it is not a one-way enzyme. Under certain conditions, its reaction runs in reverse: instead of making phosphoenolpyruvate from oxaloacetate (the gluconeogenic direction), it converts phosphoenolpyruvate back into oxaloacetate, feeding carbon into the citric acid cycle. This reverse, or anaplerotic, reaction is controlled by a chemical tag called acetylation.
When glucose is abundant, the acetyltransferase p300 attaches acetyl groups to PCK1, particularly at a residue called Lys91. That modification destabilizes the enzyme’s active site in a way that makes the gluconeogenic reaction kinetically unfavorable and promotes the reverse anaplerotic reaction instead. When energy is scarce, the deacetylase SIRT1 strips those acetyl groups off, restoring PCK1’s ability to make glucose.6PubMed Central. Dynamic Acetylation of Phosphoenolpyruvate Carboxykinase Toggles Enzyme Activity between Gluconeogenic and Anaplerotic Reactions The result is a molecular toggle: the same enzyme can push carbon toward glucose production or pull it into the energy cycle, depending on what the cell needs at the moment.
Acetylation is not the only post-translational modification that tunes PCK1. The enzyme can also be phosphorylated, ubiquitinated, and neddylated. Neddylation, in which a small protein called NEDD8 is attached to PCK1, has been found to be elevated in the livers of people with type 2 diabetes, suggesting it contributes to the dysregulated glucose production seen in that condition.7Cell Metabolism. Neddylation of PCK1 controls hepatic glucose production and is elevated in type 2 diabetes The sheer number of modification types that converge on this single enzyme underscores how tightly the body needs to regulate it.
PCK1 and Fatty Liver Disease
Metabolic-associated steatotic liver disease (MASLD, formerly called NAFLD) is now the most common chronic liver condition worldwide, and PCK1 has emerged as an unexpected player. When researchers knocked out PCK1 specifically in the livers of male mice, the animals developed hepatic fat accumulation driven by increased levels of glycerol-3-phosphate and phosphatidic acid, both of which are building blocks for triglycerides. The liver also upregulated genes involved in fatty acid uptake, compounding the problem.8Nature Communications. Deficiency of gluconeogenic enzyme PCK1 promotes metabolic-associated fatty liver disease through PI3K/AKT/PDGF axis activation in male mice The logic is straightforward: if gluconeogenesis is blocked, the metabolic intermediates that would normally be converted into glucose pile up as lipid precursors instead.
This relationship has caught the attention of drug researchers. In experimental models of MASLD, the blood pressure medication telmisartan reduced liver fat by boosting PCK1 expression, redirecting the metabolic flow of fructose away from lipid synthesis and toward glucose synthesis through a mechanism that appears to be independent of the drug’s known effects on a receptor called PPARγ.9PubMed Central. Telmisartan reverses hepatic steatosis via PCK1 upregulation: A novel PPAR-independent mechanism in experimental models of MASLD The finding is preclinical, but it hints that restoring or enhancing PCK1 activity could eventually become a therapeutic strategy for fatty liver.
A Dual Identity in Cancer
PCK1’s role in cancer depends on where the tumor arises, and the pattern is striking. In gluconeogenic organs like the liver and kidneys, PCK1 generally acts as a tumor suppressor. In hepatocellular carcinoma, the most common type of liver cancer, PCK1 expression is markedly lower in tumor tissue than in adjacent normal tissue, and patients with lower PCK1 levels tend to have worse outcomes.10PubMed Central. PCK1 Downregulation Promotes TXNRD1 Expression and Hepatoma Cell Growth via the Nrf2/Keap1 Pathway Tumors in these organs seem to benefit from shutting down gluconeogenesis, which frees up metabolic intermediates for biosynthetic pathways that support rapid cell growth.
In cancers that arise from non-gluconeogenic tissues, the picture inverts. There, PCK1 can promote tumor progression rather than suppress it.11Genes & Diseases. PCK1 dysregulation in cancer: Metabolic reprogramming, oncogenic activation, and therapeutic opportunities Part of the explanation may lie in a non-canonical ability that researchers uncovered: PCK1 can moonlight as a protein kinase, using GTP rather than the usual ATP to phosphorylate other proteins. One of its targets is Insig1/2, a gatekeeper that normally keeps lipid-producing pathways in check. By phosphorylating Insig1/2, PCK1 activates SREBP-mediated lipogenesis, effectively helping cancer cells produce the membrane lipids they need to grow and divide.12PubMed Central. A newly discovered role of metabolic enzyme PCK1 as a protein kinase to promote cancer lipogenesis This kinase function has nothing to do with classical gluconeogenesis and was entirely unexpected when first described.
The tissue-dependent duality complicates any therapeutic approach. Broadly inhibiting PCK1 might help with some cancers but could accelerate liver tumors, and vice versa. Any future cancer therapy aimed at PCK1 would probably need to be highly targeted to specific tissues and cancer types.
What Happens When PCK1 Is Missing From Birth
Cytosolic PEPCK deficiency is an extremely rare autosomal recessive condition in which both copies of the PCK1 gene carry damaging mutations. Because gluconeogenesis cannot proceed normally, affected individuals are vulnerable to life-threatening drops in blood sugar, especially during illness or any catabolic stress that increases the body’s glucose demand. Symptoms typically appear in infancy, though the clinical spectrum is broad and some cases are not recognized until adulthood.13PubMed. Genotypic and phenotypic spectrum of cytosolic phosphoenolpyruvate carboxykinase deficiency
The typical biochemical signature includes hypoglycemia triggered by infections or fasting, elevated concentrations of citric acid cycle metabolites in the urine, raised lactate levels in the blood, and mildly elevated liver enzymes. In some patients, blood glutamine concentrations are high, which researchers have flagged as a potential marker that could be incorporated into newborn screening panels. A published case report described a patient with two distinct mutations in the PCK1 gene who suffered four episodes of severe hypoglycemia, most accompanied by lactic acidosis and liver enzyme spikes, all set off by infections.14American Journal of Case Reports. Pathogenic Potential of a PCK1 Gene Variant in Cytosolic PEPCK Deficiency: A Compelling Case Study Management centers on preventing prolonged fasts and aggressively treating intercurrent illness, but no enzyme-replacement therapy exists.
Targeting PCK1 for Diabetes Treatment
Because overactive hepatic gluconeogenesis is a central feature of type 2 diabetes, PCK1 has long been an appealing drug target. The challenge is that crudely knocking down PCK1 causes its own problems, as the fatty liver and metabolic acidosis findings make clear. Instead, researchers are exploring more nuanced strategies that exploit the enzyme’s toggle between gluconeogenic and anaplerotic modes.
A small molecule called SR18292 takes this approach. Rather than eliminating PCK1, it increases the enzyme’s acetylation at Lys91, tipping it toward the reverse (anaplerotic) reaction. The result is that phosphoenolpyruvate gets funneled back into the citric acid cycle as oxaloacetate, which boosts glucose and lactate oxidation while suppressing the production of new glucose. In obese mice, liver-specific expression of a PCK1 mutant that mimics this acetylated state reduced blood sugar levels, essentially phenocopying the drug’s effect.15PubMed Central. Small molecules targeting selective PCK1 and PGC-1α lysine acetylation cause anti-diabetic action through increased lactate oxidation The elegance of this strategy is that it does not remove PCK1 activity altogether; it redirects it.
An earlier line of work tried a more direct approach: using RNA interference to partially silence PCK1 gene expression in the livers of diabetic mice. Even a modest reduction in enzyme protein, roughly halved, was enough to lower blood glucose substantially, improve glucose tolerance, and reduce circulating free fatty acids and triglycerides, all without causing liver fat buildup or lactic acidosis.16Molecular Therapy. Vector-based liver-specific RNA interference targeting phosphoenolpyruvate carboxykinase inhibits gluconeogenesis and corrects hyperglycemia in diabetic mice The key word is “partial.” Total PCK1 loss is dangerous; a measured reduction or a functional redirect seems to be the therapeutic sweet spot, at least in animals.
The PEPCK Super-Mice
No discussion of PCK1 biology is complete without the famous PEPCK-Cmus mice, one of the more memorable experiments in metabolic research. Scientists engineered mice to overexpress PCK1 in skeletal muscle, a tissue where the enzyme is normally present at very low levels. The results were dramatic. These mice could run up to five kilometers at a steady pace without stopping, while normal mice gave out after about 200 meters at the same speed. During exercise, they burned fatty acids far more efficiently and produced much less lactate than controls.17PubMed Central. Born to run; the story of the PEPCK-Cmus mouse
The muscle overexpressing mice were also hyperactive in their home cages, and the males were notably aggressive. Their skeletal muscle contained a greatly increased number of mitochondria, the organelles that generate energy through aerobic metabolism. Most strikingly, the female PEPCK-Cmus mice remained reproductively active for up to 35 months, far beyond the normal reproductive window, and the mice overall lived longer than controls. The experiment was not designed to propose a therapy; rather, it demonstrated how profoundly shifting PCK1 expression to a new tissue can reshape an organism’s energy metabolism, endurance, and even aging trajectory.
Circadian Rhythms and Pregnancy
PCK1 expression does not run at a constant rate throughout the day. In the liver, it follows a circadian rhythm synchronized with the body’s internal clock genes. This makes physiological sense: glucose production should ramp up during the fasting phase of the daily cycle and quiet down after meals. However, this rhythm is not fixed forever. During pregnancy in mice, researchers found that the normal oscillation of hepatic clock genes became dampened, and by late pregnancy, PCK1 expression had lost its rhythmic pattern entirely.18American Physiological Society (AJP – Endocrinology and Metabolism). Pregnancy-induced changes in the circadian expression of hepatic clock genes: implications for maternal glucose homeostasis The disruption of PCK1 rhythmicity during pregnancy may contribute to the altered glucose handling that characterizes late gestation, including the tendency toward insulin resistance that normally develops to ensure adequate glucose supply to the growing fetus.
Whether circadian disruptions in PCK1 contribute to gestational diabetes in humans is an open question, but the finding highlights an underappreciated dimension of the enzyme’s regulation: it is not just controlled by hormones and nutrient signals but also by the molecular clock, and anything that disrupts that clock, whether pregnancy, shift work, or chronic sleep disruption, could potentially alter gluconeogenic output.
An Ancient Enzyme With a Conserved Blueprint
PCK1 belongs to a broader family of phosphoenolpyruvate carboxykinase enzymes found across all domains of life. While the human version uses GTP as its energy source, bacterial versions exist that use ATP or even pyrophosphate instead. When researchers solved the crystal structure of a pyrophosphate-using PEPCK from the bacterium Actinomyces israelii and compared it to the structures of ATP- and GTP-specific forms, they found that all three share a conserved three-dimensional architecture with the same order of secondary structural elements and nearly identical substrate-recognition residues, except for the part of the active site that distinguishes between different energy donors.19PubMed Central. Structural comparisons of phosphoenolpyruvate carboxykinases reveal the evolutionary trajectories of these phosphodiester energy conversion enzymes The strong conservation implies that all modern PEPCKs descend from a single ancestral enzyme that existed before the major kingdoms of life diverged. The core chemistry, converting oxaloacetate and phosphoenolpyruvate back and forth, was apparently so useful that evolution preserved it across billions of years while simply swapping out the energy donor to suit different metabolic contexts.
For human biology, this deep conservation underscores why PCK1 is so tightly woven into metabolism. It is not a recent evolutionary addition bolted onto an existing system; it is one of the foundational enzymes around which gluconeogenesis and related pathways were built. That long history also helps explain why complete loss of PCK1 is so damaging: organisms have depended on this reaction for an extraordinarily long time, and there is no good backup pathway to replace it.